Point-of-Care Technologies for the Advancement of Precision Medicine in Heart, Lung, Blood, and Sleep Disorders

Microneedles as a momentous platform for psoriasis therapy and diagnosis: A state-of-the-art review

Psoriasis is a chronic, autoimmune, and non-communicable skin disease with a worldwide prevalence rate of 2-3%, creating an economic burden on global health. Some significant risk factors associated with psoriasis include genetic predisposition, pathogens, stress, medications, etc. In addition, most patients with psoriasis should also deal with comorbidities such as psoriatic arthritis, inflammatory bowel diseases, cardiovascular diseases, and psychological conditions, including suicidal thoughts. Based on its severity, the treatment approach for psoriasis is categorised into three types, i.e., topical therapy, systemic therapy, and phototherapy. Topical therapy for mild-to-moderate psoriasis faces several issues, such as poor skin permeability, low skin retention of drug formulation, greasy texture of topical vehicle, lack of controlled release, and so on. On the other arrow, systemic therapy via an oral or parenteral route of drug administration involves numerous drawbacks, including first-pass hepatic metabolism, hepatotoxicity, gastrointestinal disturbances, needle pain and phobia, and requirement of healthcare professional to administer the drug. To overcome these limitations, researchers devised a microneedle-based drug delivery system for treating mild-to-moderate and moderate-to-severe psoriasis. A single microneedle system can deliver the anti-psoriatic drugs either locally (topical) or systemically (transdermal) by adjusting the needle height without involving any pain. In this contemplate, the current review provides concise information on the pathophysiology, risk factors, and comorbidities of psoriasis, followed by their current treatment approaches and limitations. Further, it meticulously discusses the potential of microneedles in psoriasis therapy and diagnosis, along with descriptions of their patents and clinical trials.

Personalized medicine, digital technology and trust: a Kantian account

Trust relations in the health services have changed from asymmetrical paternalism to symmetrical autonomy-based participation, according to a common account. The promises of personalized medicine emphasizing empowerment of the individual through active participation in managing her health, disease and well-being, is characteristic of symmetrical trust. In the influential Kantian account of autonomy, active participation in management of own health is not only an opportunity, but an obligation. Personalized medicine is made possible by the digitalization of medicine with an ensuing increased tailoring of diagnostics, treatment and prevention to the individual. The ideal is to increase wellness by minimizing the layer of interpretation and translation between relevant health information and the patient or user. Arguably, this opens for a new level of autonomy through increased participation in treatment and prevention, and by that, increased empowerment of the individual. However, the empirical realities reveal a more complicated landscape disturbed by information 'noise' and involving a number of complementary areas of expertise and technologies, hiding the source and logic of data interpretation. This has lead to calls for a return to a mild form of paternalism, allowing expertise coaching of patients and even withholding information, with patients escaping responsibility through blind or lazy trust. This is morally unacceptable, according to Kant's ideal of enlightenment, as we have a duty to take responsibility by trusting others reflexively, even as patients. Realizing the promises of personalized medicine requires a system of institutional controls of information and diagnostics, accessible for non-specialists, supported by medical expertise that can function as the accountable gate-keeper taking moral responsibility required for an active, reflexive trust.

Wearable Device-Independent Next Day Activity and Next Night Sleep Prediction for Rehabilitation Populations

Wearable sensor-based devices are increasingly applied in free-living and clinical settings to collect fine-grained, objective data about activity and sleep behavior. The manufacturers of these devices provide proprietary software that labels the sensor data at specified time intervals with activity and sleep information. If the device wearer has a health condition affecting their movement, such as a stroke, these labels and their values can vary greatly from manufacturer to manufacturer. Consequently, generating outcome predictions based on data collected from patients attending inpatient rehabilitation wearing different sensor devices can be challenging, which hampers usefulness of these data for patient care decisions. In this article, we present a data-driven approach to combining datasets collected from different device manufacturers. With the ability to combine datasets, we merge data from three different device manufacturers to form a larger dataset of time series data collected from 44 patients receiving inpatient therapy services. To gain insights into the recovery process, we use this dataset to build models that predict a patient's next day physical activity duration and next night sleep duration. Using our data-driven approach and the combined dataset, we obtained a normalized root mean square error prediction of 9.11% for daytime physical activity and 11.18% for nighttime sleep duration. Our sleep result is comparable to the accuracy we achieved using the manufacturer's sleep labels (12.26%). Our device-independent predictions are suitable for both point-of-care and remote monitoring applications to provide information to clinicians for customizing therapy services and potentially decreasing recovery time.

Noninvasive wearable electroactive pharmaceutical monitoring for personalized therapeutics

To achieve the mission of personalized medicine, centering on delivering the right drug to the right patient at the right dose, therapeutic drug monitoring solutions are necessary. In that regard, wearable biosensing technologies, capable of tracking drug pharmacokinetics in noninvasively retrievable biofluids (e.g., sweat), play a critical role, because they can be deployed at a large scale to monitor the individuals' drug transcourse profiles (semi)continuously and longitudinally. To this end, voltammetry-based sensing modalities are suitable, as in principle they can detect and quantify electroactive drugs on the basis of the target's redox signature. However, the target's redox signature in complex biofluid matrices can be confounded by the immediate biofouling effects and distorted/buried by the interfering voltammetric responses of endogenous electroactive species. Here, we devise a wearable voltammetric sensor development strategy-centering on engineering the molecule-surface interactions-to simultaneously mitigate biofouling and create an "undistorted potential window" within which the target drug's voltammetric response is dominant and interference is eliminated. To inform its clinical utility, our strategy was adopted to track the temporal profile of circulating acetaminophen (a widely used analgesic and antipyretic) in saliva and sweat, using a surface-modified boron-doped diamond sensing interface (cross-validated with laboratory-based assays, R ² ∼ 0.94). Through integration of the engineered sensing interface within a custom-developed smartwatch, and augmentation with a dedicated analytical framework (for redox peak extraction), we realized a wearable solution to seamlessly render drug readouts with minute-level temporal resolution. Leveraging this solution, we demonstrated the pharmacokinetic correlation and significance of sweat readings.

Implementation of a Fractional-Order Electronically Reconfigurable Lung Impedance Emulator of the Human Respiratory Tree

The fractional-order lung impedance model of the human respiratory tree is implemented in this paper, using Operational Transconductance Amplifiers. The employment of such active element offers electronic adjustment of the impedance characteristics in terms of both elements values and orders. As the MOS transistors in OTAs are biased in the weak inversion region, the power dissipation and the dc bias voltage of operation are also minimized. In addition, the partial fraction expansion tool has been utilized, in order to achieve reduction of the spread of the required time-constants and scaling factors. The performance of the proposed scheme has been evaluated, at post-layout level, using MOS transistors models provided by the 0.35 μ m Austria Mikro Systeme technology CMOS process, and the Cadence IC design suite.

Precision medicine, bioanalytics and nanomaterials: toward a new generation of personalized portable diagnostics

The customization of disease treatment focused on genetic, environmental and lifestyle factors of individual patients, including tailored medical decisions and treatments, is identified as precision medicine. This approach involves the combination of various aspects such as the collection and processing of a large amount of data, the selection of optimized and personalized drug dosage for each patient and the development of selective and reliable analytical tools for the monitoring of clinical, genetic and environmental parameters. In this context, miniaturized, compact and ultrasensitive bioanalytical devices play a crucial role for achieving the goals of personalized medicine. In this review, the latest analytical technologies suitable for providing portable and easy-to-use diagnostic tools in clinical settings will be discussed, highlighting new opportunities arising from nanotechnologies, offering peculiar perspectives and opportunities for precision medicine.

Acoustofluidic devices controlled by cell phones

Acoustofluidic devices have continuously demonstrated their potential to impact medical diagnostics and lab-on-a-chip applications. To bring these technologies to real-world applications, they must be made more accessible to end users. Herein, we report on the effort to provide an easy-to-use and portable system for controlling sharp-edge-based acoustofluidic devices. With the use of a cell phone and a modified Bluetooth® speaker, on-demand and hands-free pumping and mixing are achieved. Additionally, a novel design for a sharp-edge-based acoustofluidic device is proposed that combines both pumping and mixing functions into a single device, thus removing the need for external equipment typically needed to accomplish these two tasks. These applications serve to demonstrate the potential function that acoustofluidic devices can provide in point-of-care platforms. To further this point-of-care goal, we also design a portable microscope that combines with the cell phone and Bluetooth® power supply, providing a completely transportable acoustofluidic testing station. This work serves to bolster the promising position that acoustofluidic devices have within the rapidly changing research and diagnostics fields.

Collaborative Paradigm of Preventive, Personalized, and Precision Medicine With Point-of-Care Technologies

Recent advances in biosensors, medical instrumentation, and information processing and communication technologies (ICT) have enabled significant improvements in healthcare. However, these technologies have been mainly applied in clinical environments, such as hospitals and healthcare facilities, under managed care by well-trained and specialized individuals. The global challenge of providing quality healthcare at affordable cost leads to the proposed paradigm of P reventive, Personalized, and Precision Medicine that requires a seamless use of technology and infrastructure support for patients and healthcare providers at point-of-care (POC) locations including homes, semi or pre-clinical facilities, and hospitals. The complexity of the global healthcare challenge necessitates strong collaborative interdisciplinary synergies involving all stakeholder groups including academia, federal research institutions, industry, regulatory agencies, and clinical communities. It is critical to evolve with collaborative efforts on the translation of research to technology development toward clinical validation and potential healthcare applications. This special issue is focused on technology innovation and translational research for POC applications with potential impact in improving global healthcare in the respective areas. Some of these papers were presented at the NIH-IEEE Strategic Conference on Healthcare Innovations and POC Technologies for Precision Medicine (HI-POCT) held at the NIH on November 9-10, 2015. The papers included in the Special Issue provide a spectrum of critical issues and collaborative resources on translational research of advanced POC devices and ICT into global healthcare environment.